Australian drugmakers ethics code

3 August 2008

The pharmaceutical industry trade body Medicines Australia has published its Code of Conduct Annual Report, which documents all determinations made by the independent Code of Conduct Committee during 2007-08.

The report includes the outcomes of the 52 complaints arising from the 14,633 educational events that made up the first evaluation, published in March this year. Of those 52, the Code of Conduct Committee found only 21 to be in breach of the Code - a compliance rate of 99.8%. In addition to the complaints arising from the educational events report, the Annual Report lists 24 finalized complaints that were referred through other channels. In 2006/07, a total of 38 were finalized.

Medicines Australia chief executive Ian Chalmers said the Code of Conduct Annual Report showed that, overwhelmingly, member companies are committed to a very high ethical standard of corporate behavior.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight